Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Citius Oncology, Inc.

Healthcare US CTOR

0.664USD
-0.0285(4.12%)

Last update at 2026-06-12T20:00:00Z

Day Range

0.660.71
LowHigh

52 Week Range

0.496.19
LowHigh

Fundamentals

  • Previous Close 0.69
  • Market Cap79.44M
  • Volume40485
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM3.94M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 3.15M
  • Diluted EPS TTM-0.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -23.70441M -20.57275M -12.12124M -9.71320M -0.01011M
Minority interest - - - - -
Net income -24.76137M -21.14875M -12.69724M -10.86520M -0.01011M
Selling general administrative 17.10M 15.65M 7.88M 2.86M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -20.57275M -12.12124M -4.85660M -
Ebitda -23.48638M -20.57275M -12.12124M -4.85660M -0.01011M
Depreciation and amortization - - - 9.71M -
Non operating income net other - - - - -
Operating income -23.52275M -20.57275M -12.12124M -9.71320M -
Other operating expenses 23.52M 20.57M 12.12M 9.71M -
Interest expense 0.22M 0.00000M - - -
Tax provision 1.06M 0.58M 0.58M 0.58M -
Interest income 0.04M 0.00000M - - -
Net interest income -0.18166M 0.00000M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.06M 0.58M 0.58M 1.15M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 23.52M 20.57M 12.12M 9.71M -
Cost of revenue - - - - -
Total other income expense net -0.18166M - - - -0.01011M
Discontinued operations - - - - -
Net income from continuing ops -24.76137M -21.14875M -12.69724M -5.43260M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 100.94M 84.37M 47.73M 42.69M -
Intangible assets 73.40M 73.40M 40.00M 40.00M -
Earning assets - - - - -
Other current assets 1.33M 2.70M 7.73M 2.69M -
Total liab 56.08M 38.23M 22.20M 6.42M -
Total stockholder equity 44.87M 46.14M 25.54M 36.27M -
Deferred long term liab - - - - -
Other current liab 36.26M 28.99M 19.76M 5.75M -
Common stock 0.00835M 0.00715M 0.00675M 0.00675M -
Capital stock 0.00835M 0.00715M 0.00675M 0.00675M -
Retained earnings -64.03996M -39.27859M -18.12984M -5.43260M -
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 3.92M 0.00011M 0.03M 0.29M -
Cash and equivalents - - - - -
Total current liabilities 49.49M 32.70M 21.05M 5.85M -
Current deferred revenue - - - - -
Net debt -0.12480M 3.80M -0.02652M -0.28918M -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total 3.80M 3.80M - - -
Other stockholder equity 108.90M 85.41M 43.66M 41.69M -
Property plant equipment - - - - -
Total current assets 27.54M 10.97M 7.73M 2.69M -
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables - - - - -
Long term debt 3.80M 3.80M - - -
Inventory 22.29M 8.27M 0.00000M - -
Accounts payable 13.23M 3.71M 1.29M 0.09M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 73.40M 73.40M 40.00M 40.00M -
Deferred long term asset charges - - - - -
Non current assets total 73.40M 73.40M 40.00M 40.00M -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Type yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Investments - -5.00000M 0.00000M -
Change to liabilities - - - -
Total cashflows from investing activities -5.75000M -5.00000M -1.32000M -67.32000M
Net borrowings 0.00000M 3.80M 0.00000M -
Total cash from financing activities 15.17M 4.87M 1.66M 67.66M
Change to operating activities - - - -
Net income -24.76137M -21.14875M 2.42M 0.38M
Change in cash 3.92M -0.03263M -0.25643M 0.29M
Begin period cash flow 0.00011M 0.03M 0.29M 0.00000M
End period cash flow 3.92M 0.00011M 0.03M 0.29M
Total cash from operating activities -5.49205M 0.13M -0.60130M -0.04797M
Issuance of capital stock 15.17M 0.00000M - -
Depreciation - - - -
Other cashflows from investing activities -5.75000M -5.00000M - -
Dividends paid - - - -
Change to inventory -12.64921M -2.13387M 0.00000M -
Change to account receivables - - 0.35M 0.03M
Sale purchase of stock - - - -
Other cashflows from financing activities - 1.07M 1.66M -0.38384M
Change to netincome - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 9.89M 13.20M 0.41M 0.06M
Stock based compensation 8.32M 7.50M 1.97M 0.00000M
Other non cash items 8.32M 7.50M -3.43237M -0.49302M
Free cash flow -5.49205M 0.13M -0.60130M -0.04797M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
CTOR
Citius Oncology, Inc.		 -0.0285 4.12% 0.66 - 35.59 20.14 1.36 19.25
ZTS
Zoetis Inc		 -1.83 2.25% 79.57 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.76 2.39% 31.02 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.55 3.44% 155.60 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 0.21 0.48% 43.24 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Citius Oncology, Inc.

11 Commerce Drive, Cranford, NJ, United States, 07016

  • 908 967 6677

Key Executives

Name Title Year Born
Mr. Leonard L. Mazur CEO, President & Executive Chairman 1945
Mr. Myron Z. Holubiak Secretary & Executive Vice Chairman 1947
Dr. Myron S. Czuczman M.D. Executive VP & Chief Medical Officer 1960
Mr. Jaime Bartushak Chief Financial Officer & Treasurer 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions